Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
Clinical Effectiveness Research Group, Oslo University Hospital, Oslo, Norway.
Cancer Res Commun. 2023 Nov 13;3(11):2292-2301. doi: 10.1158/2767-9764.CRC-23-0186.
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may result in suboptimal surveillance. Certain DNA copy-number alterations (CNAs) are associated with adenoma-to-carcinoma progression. We aimed to evaluate whether these molecular features can better predict an individual's risk of me-CRC than the morphologic advanced adenoma features.In this nested case-control study, 529 individuals with a single adenoma at first colonoscopy were selected from a Norwegian adenoma cohort. DNA copy-number profiles were determined, by low-coverage whole-genome sequencing. Prevalence of CNAs in advanced and non-advanced adenomas and its association (OR) with me-CRC was assessed. For the latter, cases (with me-CRC) were matched to controls (without me-CRC) on follow-up, age and sex.CNAs associated with adenoma-to-carcinoma progression were observed in 85/267 (32%) of advanced adenomas and in 27/262 (10%) of non-advanced adenomas. me-CRC was statistically significantly associated, also after adjustment for other variables, with age at baseline [OR, 1.14; 95% confidence interval CI), 1.03-1.26; P = 0.012], advanced adenomas (OR, 2.46; 95% CI, 1.50-4.01; P < 0.001) and with the presence of ≥3 DNA copy-number losses (OR, 1.90; 95% CI. 1.02-3.54; P = 0.043).Molecularly-defined high-risk adenomas were associated with me-CRC, but the association of advanced adenoma with me-CRC was stronger.
Identifying new biomarkers may improve prediction of me-CRC for individuals with adenomas and optimize surveillance intervals to reduce risk of colorectal cancer and reduce oversurveillance of patients with low risk of colorectal cancer. Use of DNA CNAs alone does not improve prediction of me-CRC. Further research to improve risk classification is required.
评估这些分子特征是否能比形态学上的高级腺瘤特征更好地预测个体发生结直肠癌的风险。
在这项嵌套病例对照研究中,从挪威腺瘤队列中选择了首次结肠镜检查时有单个腺瘤的 529 名个体。通过低覆盖率全基因组测序确定 DNA 拷贝数谱。评估高级和非高级腺瘤中 CNA 的患病率及其与 me-CRC 的关联(OR)。对于后者,病例(有 me-CRC)按随访、年龄和性别与对照(无 me-CRC)匹配。
在 267 例高级腺瘤中的 85 例(32%)和 262 例非高级腺瘤中的 27 例(10%)中观察到与腺瘤癌变进展相关的 CNA。在调整其他变量后,me-CRC 仍与基线时的年龄呈统计学显著相关[OR,1.14;95%置信区间(CI),1.03-1.26;P = 0.012]、高级腺瘤(OR,2.46;95% CI,1.50-4.01;P < 0.001)和存在≥3 个 DNA 拷贝数缺失(OR,1.90;95% CI,1.02-3.54;P = 0.043)。
分子定义的高危腺瘤与 me-CRC 相关,但高级腺瘤与 me-CRC 的相关性更强。
识别新的生物标志物可能会改善对有腺瘤的个体发生 me-CRC 的预测,并优化监测间隔,以降低结直肠癌的风险,并减少对结直肠癌风险低的患者的过度监测。单独使用 DNA CNA 并不能提高 me-CRC 的预测能力。需要进一步研究以改善风险分类。